We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 48
Most popular |Most recent


List it or Lose it: The Federal Circuit Weighs in on the Amgen v. Hospira Discovery Dispute

USA - August 11 2017 The Federal Circuit issued its opinion in the Amgen v. Hospira appeal (16-2179) on August 10, 2017, dismissing the appeal for lack of jurisdiction and...


The Ramifications of Leaving the Patent Dance Floor

USA - August 3 2017 While the Supreme Court held in Amgen v. Sandoz that biosimilar applicants cannot be forced with a federal injunction to provide a copy of their...

Tasha M. Francis.


PTAB Splits on Instituting Challenges to Herceptin Patents

USA - August 2 2017 On July 27th, the PTAB issued institution decisions in five IPRs brought by Hospira challenging four Genentech patents related to Herceptin...

Casey Kraning-Rush.


The Amgen v. Sandoz Disclosure Disputes Continue

USA - July 27 2017 A theme emerging in biosimilar litigation is when - and how much - discovery is available to reference product sponsors. The Supreme Court in Amgen...

Ron Vogel.


Pfizer Takes Aim at Herceptin Patent at the PTAB

USA - July 12 2017 Pfizer has shown its muscle in the biosimilars field, purchasing Hospira in 2015 and launching the second biosimilar on the U.S. market, Inflectra...

Casey Kraning-Rush.